{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:37:56Z","timestamp":1770298676884,"version":"3.49.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold> Anti-tumor necrosis factor (TNF) agents have been regarded as the most effective treatment for ankylosing spondylitis (AS) so far. However, economic factors limited the prescription of original biologicals in China. Yisaipu<jats:sup>\u00ae<\/jats:sup> is a biosimilar for etanercept as pre fill syringes (PFS), which has entered China\u2019s national medical insurance catalog for more than 10\u00a0yr and was widely used because it greatly reduced the economic burden of AS patients. Yisaipu<jats:sup>\u00ae<\/jats:sup> is provided subcutaneous injection in hospital setting only. We collected clinical data of AS patients before, during and after COVID-19 epidemic, in an attempt to investigate the advantages and disadvantages of original biologicals and Yisaipu<jats:sup>\u00ae<\/jats:sup> during regular follow up and COVID-19 epidemic.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> AS patients who received original biologicals or Yisaipu<jats:sup>\u00ae<\/jats:sup> in our department for more than 1\u00a0yr were included in our study. General data, demographic characteristics, disease activity, quality of life and medical compliance were collected from regular visits. The patients were followed up through telephone interviews from April 20th to 27th, 2020 about the overall impact of the COVID-19 epidemic.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> There was no significant difference in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score-CRP (ASDAS-CRP) between the two groups. Health Assessment Questionnaire for Spondyloarthropathies (HAQ-s) showed that Yisaipu<jats:sup>\u00ae<\/jats:sup> group was superior to original biological group in terms of eating, gripping and driving. In addition, the medical cost of Yisaipu<jats:sup>\u00ae<\/jats:sup> was lower than that of original biologicals. The overall impact of the COVID-19 epidemic on patients of original biological group was comparatively smaller than that on Yisaipu<jats:sup>\u00ae<\/jats:sup> group.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Yisaipu<jats:sup>\u00ae<\/jats:sup> provided AS patients with an economical selection during regular follow-up, while original biologicals had certain advantages in the COVID-19 epidemic setting, including a longer time interval between two drug administrations and the self-injection dose form of medication.<\/jats:p>","DOI":"10.3389\/fphar.2021.692768","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T05:02:50Z","timestamp":1630904570000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Yisaipu\u00ae Provide AS Patients With an Economical Therapeutic Option While Original Biologicals are More Advantageous in the COVID-19 Epidemic Situation"],"prefix":"10.3389","volume":"12","author":[{"given":"Hongjuan","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanqiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoran","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huji","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"vii5","DOI":"10.1093\/rheumatology\/key059","article-title":"20 Years of Experience with Tumour Necrosis Factor Inhibitors: What Have We Learned?","volume":"57","author":"Caporali","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"B2","volume-title":"China Statistics Yearbook","year":"2019"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1097\/00124743-199912000-00020","article-title":"Development of a Questionnaire to Investigate Patient Compliance with Antirheumatic Drug Therapy","volume":"26","author":"De Klerk","year":"1999","journal-title":"J. Rheumatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/rheumatology\/kep083","article-title":"Paradoxical Adverse Events of Anti-tumour Necrosis Factor Therapy for Spondyloarthropathies: A Retrospective Study","volume":"48","author":"Fouache","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1017\/S0950268817001133","article-title":"Spatiotemporal Analysis of Tuberculosis Incidence and its Associated Factors in Mainland China","volume":"145","author":"Guo","year":"2017","journal-title":"Epidemiol. Infect."},{"key":"B6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer Risk in Patients with Spondyloarthritis Treated with TNF Inhibitors: A Collaborative Study from the ARTIS and DANBIO Registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-Alpha: Structure, Function and Interaction with Anti-TNF Agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.rdc.2020.04.001","article-title":"Risk of Malignancy in Spondyloarthritis: A Systematic Review","volume":"46","author":"Karmacharya","year":"2020","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"B9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","article-title":"Consensus-based Recommendations for the Use of Biosimilars to Treat Rheumatological Diseases","volume":"77","author":"Kay","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1056\/NEJMc2003717","article-title":"Detection of Covid-19 in Children in Early January 2020 in Wuhan, China","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.xNYAS4621","article-title":"TNF-alpha Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed Under Conditions of Standard Clinical Practice","volume":"1173","author":"Marchesoni","year":"2009","journal-title":"Ann. N. Y Acad. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"CD005468","DOI":"10.1002\/14651858.CD005468.pub2","article-title":"TNF-alpha Inhibitors for Ankylosing Spondylitis","volume":"4","author":"Maxwell","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of Synthetic and Biological DMARDs: A Systematic Literature Review Informing the 2016 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e000397","DOI":"10.1136\/rmdopen-2016-000397","article-title":"Efficacy and Safety of Non-pharmacological and Non-biological Pharmacological Treatment: A Systematic Literature Review Informing the 2016 Update of the ASAS\/EULAR Recommendations for the Management of Axial Spondyloarthritis","volume":"3","author":"Regel","year":"2017","journal-title":"RMD Open"},{"key":"B15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nrrheum.2012.84","article-title":"The Advent of Biosimilar Therapies in Rheumatology--\"O Brave New World\"","volume":"8","author":"Scheinberg","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of Worldwide Prevalence of Chronic Hepatitis B Virus Infection: A Systematic Review of Data Published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial Spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of Diagnostic Criteria for Ankylosing Spondylitis. A Proposal for Modification of the New York Criteria","volume":"27","author":"Van der Linden","year":"1984","journal-title":"Arthritis Rheum."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/art.4104210.1002\/acr.24025","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13075-019-1995-7","article-title":"Depression in Ankylosing Spondylitis and the Role of Disease-Related and Contextual Factors: A Cross-Sectional Study","volume":"21","author":"Webers","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/s2665-9913(19)30013-x","article-title":"IBI303, a Biosimilar to Adalimumab, for the Treatment of Patients with Ankylosing Spondylitis in China: A Randomised, Double-Blind, Phase 3 Equivalence Trial","volume":"1","author":"Xu","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40744-021-00276-1","article-title":"Safety and Efficacy of Prefilled Liquid Etanercept-Biosimilar Yisaipu for Active Ankylosing Spondylitis: A Multi-Center Phase III Trial","volume":"8","author":"Zhao.","year":"2021","journal-title":"Rheumatol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1002\/acr.20575","article-title":"Measures of Symptoms and Disease Status in Ankylosing Spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S)","volume":"63","author":"Zochling","year":"2011","journal-title":"Arthritis Care Res. (Hoboken)"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.692768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T05:02:55Z","timestamp":1630904575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.692768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":23,"alternative-id":["10.3389\/fphar.2021.692768"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.692768","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"article-number":"692768"}}